missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Felzartamab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
Marke: Invitrogen™ MA559211
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Felzartamab is a fully human recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CD38 on plasma cells. CD38 is a multifunctional enzyme that is widely expressed in both immune and non-hematopoietic cells. It plays a critical role in NAD+ metabolism by converting NAD+ to ADP-ribose and nicotinamide, which are key molecules in cellular signaling and energy metabolism. Structurally, CD38 is a transmembrane glycoprotein with ectoenzyme activity, meaning that its enzymatic functions occur on the outer surface of the cell membrane. CD38's activity is particularly significant in aging, as its expression increases in immune cells due to the senescence-associated secretory phenotype. This elevation in CD38 activity contributes to decreased NAD+ levels, which is associated with various age-related diseases. CD38 has also been identified as a potential therapeutic target for conditions such as renal immune diseases and age-related metabolic decline.
Spezifikation
| Felzartamab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur